1. Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
   Yan Liang et al, 2024, Frontiers in Pharmacology CrossRef
2. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions
   Yujun Tong et al, 2024, Frontiers in Immunology CrossRef
3. Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook
   Yongshun Liu et al, 2024, Molecular Pharmaceutics CrossRef
4. ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer
   Marco La Ferla et al, 2019, Frontiers in Oncology CrossRef
5. Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
   Inna P. Ganshina et al, 2021, Journal of Modern Oncology CrossRef
6. TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer
   Xiaoyue Liu et al, 2022, OncoTargets and Therapy CrossRef
7. Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer
   Narges K Tafreshi et al, 2020, World Journal of Clinical Oncology CrossRef
8. Toxicarioside O Inhibits Cell Proliferation and Epithelial-Mesenchymal Transition by Downregulation of Trop2 in Lung Cancer Cells
   Wu-Ping Zheng et al, 2021, Frontiers in Oncology CrossRef
9. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer
   Neelima Vidula et al, 2022, Breast Cancer Research and Treatment CrossRef
10. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments
    Shota Omori et al, 2022, Journal of Cancer Research and Clinical Oncology CrossRef
11. Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements
    Liqin Yao et al, 2023, Frontiers in Oncology CrossRef
12. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
    María Gion et al, 2024, Breast Cancer Research and Treatment CrossRef
13. Programming tissue-sensing T cells that deliver therapies to the brain
    Milos S. Simic et al, 2024, Science CrossRef